The Trump administration promised to drastically cut prescription drugs prices in the US, where the industry makes most of its money.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Snacking conglomerates all agree: Petcare mergers and acquisitions are the cat’s pajamas. Just ask General Mills.
Has Bob Iger now done it? Has he restored the magic, the thing defeated activist agitator Carl Icahn said was missing?
Charging infrastructure remains a barrier in EV adoption.
The UK and US announced a “historic” trade deal Thursday that does little to reduce Washington’s overall global trade war.
Honeywell may just be the next conglomerate to split into various pieces. At least if Elliott Investment Management has its way.
A treasure trove of genetic data may hold the key to a revolution in drug development, but it offers no clues for building a business.
De Beers, the world’s largest diamond producer, said it plans to shutter its lab-grown jewelry brand LightBox.
Nestlé and Formula 1 announced on Monday that starting with the upcoming 2025 season KitKat will be the sport’s “official chocolate bar.”
Dissapointing results for two mid-stage trials strikes a blow in Abbvie’s expensive pipeline-via-M&A strategy.
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Netflix is rolling out the first major redesign of its home hub since 2013, hoping people might watch more if inundated with less.
Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.